Group 1 - The A-share market has reached 3800 points for the first time in ten years, with most brokerages believing that the internal and external fundamentals and liquidity conditions do not present significant bearish factors, supporting a continued upward trend in the market [1][9] - Citic Securities indicates that the current market rally is primarily driven by institutional investors rather than retail investors, emphasizing the importance of focusing on industry trends and performance rather than merely liquidity [2] - Guotai Junan Securities expresses optimism about the A-share market, citing multiple factors such as capital market reforms and improved risk appetite, which are expected to support the performance of Chinese assets [3] Group 2 - Galaxy Securities warns of potential increased volatility in the A-share market as it enters an acceleration phase, despite a generally positive mid-term outlook [4][6] - Zheshang Securities advises investors to ignore short-term fluctuations and focus on medium-term strategies, suggesting to increase positions near key support levels [10][11] - Xinyi Securities highlights the importance of identifying low-position opportunities in technology growth sectors while also considering cyclical sectors with growth potential [12] Group 3 - Huatai Securities notes that the consensus on the upward trend in the market is strengthening, driven by improvements in domestic fundamentals and liquidity [7][8] - The market is expected to maintain its strength until early September, with a shift in focus from short-term momentum to mid-term developments post-September [6] - The overall sentiment in the market remains bullish, with a focus on sectors such as AI, innovative pharmaceuticals, and military industries as key strategic allocations [8][13]

券商研报被上市公司"点名"风波延续。5月21日晚，近期处于市场关注焦点的华熙生物再发一文，就5月17日的发文内容做进一步解释，并再度提及 券商研报。回顾此前，华熙生物一次性点名华泰证券、西部证券、国金证券等多家券商研报，并直指其中存在误导性"结论"。有业内人士表示，上 市公司对券商研报的质疑，关键意义在于重新定义上市公司与券商投研的互动关系，从这一角度看，或存在积极意义。对券商研究所而言，未来需 要不断提升专业水平，尽量减少被质疑的可能性。论据专业性、逻辑严谨性是未来研报的核心。 华熙生物再发文 近期，备受市场关注的华熙生物在5月21日再度发文，就此前5月17日的发文内容做进一步解释，也再度提及券商研报内容。 在华熙生物看来，部分券商研报所涉及的企业在医美填充领域并没有获得任何三类医疗器械注册证，所以并不具备对医美填充成分技术的评估和宣 传条件。券商研报中这种B优于A的结论，是缺乏任何公开数据或国内外科研论文结论支持的。 回顾5月17日，华熙生物曾在其官方微信号发文指出，2022年开始，随着资本市场不断追求新的公司题材，重组胶原蛋白概念被看似幸运地选中 了。为了营造比透明质酸产业更大的预期，围绕某重组胶原企业 ...